复发性乳腺癌的预后因素：与复发部位、无病生存期、女性性激素受体、倍体及组织学恶性程度分级的关系
Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading.
作者信息
Blanco G, Holli K, Heikkinen M, Kallioniemi O P, Taskinen P
机构信息
Department of Radiotherapy, Oulu University Central Hospital, Finland.
出版信息
Br J Cancer. 1990 Jul;62(1):142-6. doi: 10.1038/bjc.1990.247.
Abstract
Site of first recurrence, disease-free interval (DFI), female sex steroid receptors, ploidy measurements as well as histological grading have been analysed as potentially valuable predictive factors in 313 cases of recurrent breast cancer. Univariate and multivariate analyses show histological grading, site of recurrence and disease free interval to be useful prognostic variables when assessing prognosis once disease has recurred. High concentrations of oestrogen receptors (ER) were found in patients with bone metastases, whereas lower concentrations of ER were related to visceral recurrences. Ploidy measurements failed in this study to give any predictive information once disease recurred.
摘要
在313例复发性乳腺癌病例中，首次复发部位、无病生存期（DFI）、女性性激素受体、倍体测量以及组织学分级已被分析为潜在有价值的预测因素。单因素和多因素分析表明，在评估疾病复发后的预后时，组织学分级、复发部位和无病生存期是有用的预后变量。骨转移患者中发现雌激素受体（ER）浓度较高，而较低的ER浓度与内脏复发有关。在这项研究中，一旦疾病复发，倍体测量未能提供任何预测信息。
相似文献
1
Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading.复发性乳腺癌的预后因素：与复发部位、无病生存期、女性性激素受体、倍体及组织学恶性程度分级的关系
Br J Cancer. 1990 Jul;62(1):142-6. doi: 10.1038/bjc.1990.247.
2
Sex steroid receptors, S-phase fraction and DNA ploidy as determinants of the risk of relapse and death of female breast cancer.性类固醇受体、S期分数和DNA倍性作为女性乳腺癌复发和死亡风险的决定因素。
Anticancer Res. 1992 May-Jun;12(3):677-82.
3
Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers.2257例可手术乳腺癌长期随访后类固醇受体的预后价值
Br J Cancer. 1996 Jun;73(12):1545-51. doi: 10.1038/bjc.1996.291.
4
Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.通过联合评估p53和前列腺特异性抗原的表达增强乳腺癌预后预测
Br J Cancer. 1999 Oct;81(3):490-5. doi: 10.1038/sj.bjc.6690720.
5
Histological grade and steroid receptor content of primary breast cancer--impact on prognosis and possible modes of action.原发性乳腺癌的组织学分级和类固醇受体含量——对预后的影响及可能的作用方式
Br J Cancer. 1988 Oct;58(4):480-6. doi: 10.1038/bjc.1988.245.
6
7
8
Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.雌激素受体阳性、人表皮生长因子受体2阴性乳腺癌的淋巴结转移灶中孕激素受体表达缺失与他莫昔芬治疗后复发相关。
J Clin Pathol. 2017 Nov;70(11):954-960. doi: 10.1136/jclinpath-2016-204304. Epub 2017 Apr 17.
9
Steroid hormone receptors in the management of human breast cancer.类固醇激素受体在人类乳腺癌治疗中的应用
Ann Clin Res. 1980 Oct;12(5):202-7.
10
Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients.乳腺癌中DNA倍体和细胞增殖的短期意义：对308例患者预后标志物的多变量分析
J Clin Pathol. 1999 Aug;52(8):604-11. doi: 10.1136/jcp.52.8.604.
引用本文的文献
1
Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.三阴性乳腺癌高度异质相关基因：潜在的诊断和预后生物标志物。
BMC Cancer. 2021 May 31;21(1):644. doi: 10.1186/s12885-021-08318-1.
2
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials.通过预后和内在亚型及生物标志物分析评估哌柏西利联合内分泌治疗对仅骨转移疾病患者的疗效：PALOMA-2和PALOMA-3临床试验的联合分析
Breast Cancer Res Treat. 2020 Nov;184(1):23-35. doi: 10.1007/s10549-020-05782-4. Epub 2020 Aug 11.
3
Significance of re-biopsy for recurrent breast cancer in the immune tumour microenvironment.免疫肿瘤微环境中复发性乳腺癌再次活检的意义。
Br J Cancer. 2018 Aug;119(5):572-579. doi: 10.1038/s41416-018-0197-4. Epub 2018 Jul 23.
4
Effecst of Patho- Biological Factors on the Survival of Recurrent Breast Cancer Cases.病理生物学因素对复发性乳腺癌病例生存情况的影响。
Asian Pac J Cancer Prev. 2018 Apr 25;19(4):949-953. doi: 10.22034/APJCP.2018.19.4.949.
5
High Expression of Sphingosine Kinase 1 in Estrogen and Progesterone Receptors-Negative Breast Cancer.鞘氨醇激酶1在雌激素和孕激素受体阴性乳腺癌中的高表达
Iran J Pathol. 2017 Summer;12(3):218-224. Epub 2017 May 30.
6
Novel Strategies to Improve the Endocrine Therapy of Breast Cancer.改善乳腺癌内分泌治疗的新策略
Oncol Rev. 2017 May 16;11(1):323. doi: 10.4081/oncol.2017.323. eCollection 2017 Mar 3.
7
Monocytes and macrophages, implications for breast cancer migration and stem cell-like activity and treatment.单核细胞和巨噬细胞对乳腺癌迁移、干细胞样活性及治疗的影响
Oncotarget. 2015 Jun 10;6(16):14687-99. doi: 10.18632/oncotarget.4189.
8
Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions.克服转移性乳腺癌中的内分泌耐药性：当前证据与未来方向。
World J Clin Oncol. 2014 Dec 10;5(5):990-1001. doi: 10.5306/wjco.v5.i5.990.
9
Co-ordination of cell cycle, migration and stem cell-like activity in breast cancer.乳腺癌中细胞周期、迁移及干细胞样活性的协调作用
Oncotarget. 2014 Sep 15;5(17):7833-42. doi: 10.18632/oncotarget.2312.
10
Prognostic factors and survival in metastatic breast cancer: A single institution experience.转移性乳腺癌的预后因素与生存情况：单机构经验
Rep Pract Oncol Radiother. 2013 Feb 14;18(3):127-32. doi: 10.1016/j.rpor.2013.01.001.
本文引用的文献
1
Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years.乳腺癌的组织学分级与预后；对1409例病例的研究，其中359例已随访15年。
Br J Cancer. 1957 Sep;11(3):359-77. doi: 10.1038/bjc.1957.43.
2
The value of estrogen and progesterone receptors in the treatment of breast cancer.雌激素和孕激素受体在乳腺癌治疗中的价值。
Cancer. 1980 Dec 15;46(12 Suppl):2884-8. doi: 10.1002/1097-0142(19801215)46:12+<2884::aid-cncr2820461429>3.0.co;2-u.
3
Relationship between primary breast tumor receptor status and patient survival.原发性乳腺肿瘤受体状态与患者生存率之间的关系。
Cancer. 1980 Dec 15;46(12 Suppl):2765-9. doi: 10.1002/1097-0142(19801215)46:12+<2765::aid-cncr2820461404>3.0.co;2-c.
4
Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer.雌激素受体、转移性疾病部位与复发性乳腺癌的生存情况
Eur J Cancer (1965). 1981 Apr;17(4):449-53. doi: 10.1016/0014-2964(81)90254-1.
5
Prognostic factors in metastatic breast cancer.转移性乳腺癌的预后因素
Cancer Clin Trials. 1981 Fall;4(3):237-47.
6
Survival after recurrence of breast cancer.乳腺癌复发后的生存情况。
Can Med Assoc J. 1981 Jun 15;124(12):1591-5.
7
The value of prognostic parameters for the stratification of advanced breast cancer patients.晚期乳腺癌患者分层中预后参数的价值。
J Cancer Res Clin Oncol. 1982;102(3):289-99. doi: 10.1007/BF00411349.
8
Female sex steroid receptor status in primary and metastatic breast carcinoma and its relationship to serum steroid peptide hormone levels.原发性和转移性乳腺癌中女性性激素受体状态及其与血清甾体肽激素水平的关系。
Int J Cancer. 1980 Jul 15;26(1):13-21. doi: 10.1002/ijc.2910260104.
9
The metastasis-free interval following curative treatment for breast cancer.乳腺癌根治性治疗后的无转移生存期。
Int J Radiat Oncol Biol Phys. 1984 Jan;10(1):63-7. doi: 10.1016/0360-3016(84)90413-9.
10
Pathologic findings from the National Surgical Adjuvant Project for Breast Cancers (protocol no. 4). X. Discriminants for tenth year treatment failure.国家乳腺癌手术辅助项目（方案编号4）的病理研究结果。X. 十年治疗失败的判别因素。
Cancer. 1984 Feb 1;53(3 Suppl):712-23. doi: 10.1002/1097-0142(19840201)53:3+<712::aid-cncr2820531320>3.0.co;2-i.
Zotero 插件